SEC Form 4 · accession 0001209191-18-045588
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Posner
Director
Period of report
Aug 2, 2018
Accepted (ET)
Aug 6, 2018 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $17.94 | Aug 2, 2018 | A | 35,000 | A | — | Aug 2, 2028 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable in three equal annual installments beginning on August 2, 2019, subject to the reporting person's continued service as a director through each such vesting date.